The EPS projection of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for period quarter completed 2016-12-31 is $0.09.
The EPS estimates given a week and 30-days ago were $0.09 and $0.09 correspondingly. This number 60 and 90 days before was $0.09 and $0.09 respectively. However, over last week ago, the change in EPS estimate is 0%.
For the quarter completed 2 mean estimate is $0.09 based on 2 EPS estimations. As on 2016-07-27 estimated EPS stood at $-0.01 showing surprise of $0.01, or 50%. Following the disclosed forecasts, the standard deviation is $0.07.
The upgrade in EPS revisions were 0 a week earlier against negative revisions of 0. In last 1- month and 60-days, the upgrade in EPS revisions were 0 and 0 correspondingly, whereas for a quarter and 120-days earlier, it was 1 and 2 in that sequence.
The negative revisions of earnings per-share in the last 1-month and 60-days were 5 and 4 in that order. However, a quarter and 120-days earlier, this count was 2 and 1 correspondingly.
EPS revisions downgrade and upgrade in the last 18 days were 3 and 0, correspondingly.
Quarterly Sales Estimates
The arithmetic mean of apparent annual sales of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is $638.413 and the median is $638.413. The estimate is stated by 2 analysts for the fiscal 2017.
The highest yearly projection is $720.076 and lowest sales mark is $556.751. This results a standard deviation of $115.488.
Almost 2 have revised sales target positively in the past week and 2 have downgraded forecasts. Depending on the stated estimates, the calculated change in target against the past week is 0%.
Nearly 2 revised sales projections positively over the past month and 2 have downgraded forecasts. It leads to a mean estimate deviation of -3.683%.
Just about 2 have revised sales forecast positively over the quarter and 2 have downgraded forecasts, giving a deviation of -5.726%.
1 Chart Pattern Every Investor Should Know